Fulciniti, Mariateresa

Expanded encyclopaedias of DNA elements in the human and mouse genomes

The ENCODE Project Consortium, Abascal, F., Acosta, R., Addleman, N. J., Adrian, J., Afzal, V., Ai, R., Aken, B., Akiyama, J. A., Jammal, O. A., et al. (2020) · Nature

Genomics and Chromatin DynamicsEpigenetics and DNA Methylation

Cited by 2,378

Heterogeneity of genomic evolution and mutational profiles in multiple myeloma

Bolli, N., Avet-Loiseau, H., Wedge, D. C., Van Loo, P., Alexandrov, L. B., Martincorena, I., Dawson, K. J., Iorio, F., Nik-Zainal, S., Bignell, G. R., et al. (2014) · Nature Communications

Multiple Myeloma Research and TreatmentsCancer Genomics and Diagnostics

Cited by 875

Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma

Richardson, P. G., Jacobus, S. J., Weller, E. A., Hassoun, H., Lonial, S., Raje, N. S., Medvedova, E., McCarthy, P. L., Libby, E. N., Voorhees, P. M., et al. (2022) · New England Journal of Medicine

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 487

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

Walker, B. A., Mavrommatis, K., Wardell, C. P., Ashby, T. C., Bauer, M., Davies, F. E., Rosenthal, A., Wang, H., Qu, P., Hoering, A., et al. (2018) · Blood

Multiple Myeloma Research and TreatmentsAcute Myeloid Leukemia Research

Cited by 475

Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma

Mimura, N., Fulciniti, M., Gorgun, G., Tai, Y.-T., Cirstea, D., Santo, L., Hu, Y., Fabre, C., Minami, J., Ohguchi, H., et al. (2012) · Blood

Endoplasmic Reticulum Stress and DiseaseMultiple Myeloma Research and Treatments

Cited by 432

Genomic landscape and chronological reconstruction of driver events in multiple myeloma

Maura, F., Bolli, N., Angelopoulos, N., Dawson, K. J., Leongamornlert, D., Martincorena, I., Mitchell, T. J., Fullam, A., Gonzalez, S., Szalat, R., et al. (2019) · Nature Communications

Multiple Myeloma Research and TreatmentsCancer Genomics and Diagnostics

Cited by 278

Genomic patterns of progression in smoldering multiple myeloma

Bolli, N., Maura, F., Minvielle, S., Gloznik, D., Szalat, R., Fullam, A., Martincorena, I., Dawson, K. J., Samur, M. K., Zamora, J., et al. (2018) · Nature Communications

Multiple Myeloma Research and TreatmentsCancer Genomics and Diagnostics

Cited by 222

RETRACTED: Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis

Tai, Y.-T., Fulciniti, M., Hideshima, T., Song, W., Leiba, M., Li, X.-F., Rumizen, M., Burger, P., Morrison, A., Podar, K., et al. (2007) · Blood

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 109

Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma

Gullà, A., Hideshima, T., Bianchi, G., Fulciniti, M., Kemal Samur, M., Qi, J., Tai, Y.-T., Harada, T., Morelli, E., Amodio, N., et al. (2018) · Leukemia

Cancer-related gene regulationMultiple Myeloma Research and Treatments

Cited by 102

Genome-wide somatic alterations in multiple myeloma reveal a superior outcome group

Samur, M. K., Aktas Samur, A., Fulciniti, M., Szalat, R., Han, T., Shammas, M., Richardson, P., Magrangeas, F., Minvielle, S., Corre, J., et al. (2020) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsCancer Genomics and Diagnostics

Cited by 70

Antigen-mediated regulation in monoclonal gammopathies and myeloma

Nair, S., Sng, J., Boddupalli, C. S., Seckinger, A., Chesi, M., Fulciniti, M., Zhang, L., Rauniyar, N., Lopez, M., Neparidze, N., et al. (2018) · JCI Insight

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 60

Deep response in multiple myeloma: a critical review.

Fulciniti, M., Munshi, N. C., & Martinez-Lopez, J. (2015) · BioMed Research International

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 40

Structural basis for the midnolin-proteasome pathway and its role in suppressing myeloma

Nardone, C., Gao, J., Seo, H.-S., Mintseris, J., Ort, L., Yip, M. C. J., Negasi, M., Besschetnova, A. K., Kamitaki, N., Gygi, S. P., et al. (2025) · Molecular Cell

Ubiquitin and proteasome pathwaysProtein Degradation and Inhibitors

Cited by 22

Structural basis for the midnolin-proteasome pathway and its role in suppressing myeloma

Nardone, C., Gao, J., Seo, H.-S., Mintseris, J., Ort, L., Yip, M. C. J., Negasi, M., Besschetnova, A. K., Kamitaki, N., Gygi, S. P., et al. (2025) · Molecular Cell

Ubiquitin and proteasome pathwaysProtein Degradation and Inhibitors

Cited by 22

IgM-MM is predominantly a pre–germinal center disorder and has a distinct genomic and transcriptomic signature from WM

Bazarbachi, A. H., Avet-Loiseau, H., Szalat, R., Samur, A. A., Hunter, Z., Shammas, M., Corre, J., Fulciniti, M., Anderson, K. C., Parmigiani, G., et al. (2021) · Blood

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 21

Development of hyperdiploidy starts at an early age and takes a decade to complete

Samur, M. K., Aktas Samur, A., Shah, P., Park, J. S., Fulciniti, M., Shammas, M., Corre, J., Anderson, K. C., Parmigiani, G., Avet-Loiseau, H., et al. (2025) · Blood

Multiple Myeloma Research and TreatmentsCancer Genomics and Diagnostics

Cited by 13